Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 218

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

The generation of a humanized, non‐mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties

Bolt, Sarah, Routledge, Edward, Lloyd, Irene, Chatenoud, Lucienne, Pope, Heather, Gorman, Scott D., Clark, Mike, Waldmann, Herman·1993·European Journal of Immunology

Abstract

CD3 antibodies are proven immunosuppressants capable of reversing transplant rejection episodes. Their general application has been limited both by their immunogenicity and, in particular, by the “first‐dose” cytokine‐release syndrome experienced by patients after the initial administration of antibody. We have produced a set of variants of the humanized YTH 12.5 CD3 monoclonal antibody (mAb) (Routledge et al., Eur. J. Immunol. 1991. 21: 2717) bearing different human heavy (H) chain constant regions, with the intention of finding a form of the antibody that is not able to activate T cells. Comparison of the variants having γl, γ2, γ3 and γ4 H chains in a competitive binding assay showed that antibody avidity was not affected by IgG subclass. Using a sensitive indicator of FcR binding activity (the capacity of the CD3 mAb to redirect cytotoxic T cells to kill the monocytic cell line U‐937) we demonstrated a functional hierarchy of γl = γ4 α2 = γ3 mb > γ2. An aglycosyl version of the γl CD3 mAb, produced by site‐directed mutagenesis (Asn 297 to Ala), still had considerable activity in this assay (intermediate to the γl and α2 CD3 mAb), albeit at a level approximately 10‐fold lower than that of the parental γl form. When we tested their ablity to stimulate T cell proliferation in vitro in the presence of 5% human serum, all of the wild‐type immunoglobulin isotypes were found to be active, although there were T cell donor‐dependent variations in the extent of the responses. The aglycosyl γl mAb was, however, completely non‐mitogenic in all of ten donors tested, unless the assay was performed in IgG‐free medium. Despite being non‐stimulatory, this mAb was also able to inhibit the mixed lymphocyte reaction responses of both naive and primed T cells. Comparison of the yl and aglycosyl γ1 mAb in an experimental mouse model for CD3 mAb‐induced cytokine release indicated that removal of the carbohydrate moiety from the γl constant region reduced the in vivo tumor necrosis factor‐a response by a factor of at least 16‐fold. These data suggest that the aglycosyl γl CD3 mAb is a promising candidate for immunosuppressive therapy without “first dose” side effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/eji.1830230216

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 218

Metadata

Authors
Bolt, S., Routledge, E., Lloyd, I., Chatenoud, L., Pope, H., Gorman, S. D., Clark, M., & Waldmann, H.
Venue
European Journal of Immunology
Publisher
Wiley
Published
1993-02
Volume
23
Issue
2
Pages
403-411
ISSN
  • 0014-2980 (ISSN-L)
  • 1521-4141
OpenAlex
W2158637103
Cited by
218
References
1
FWCI
3.78
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The generation of a humanized, non‐mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. https://app.cochat.ai/papers/10.1002/eji.1830230216
The paper
Bolt, S., Routledge, E., Lloyd, I., Chatenoud, L., Pope, H., Gorman, S. D., Clark, M., & Waldmann, H. (1993). The generation of a humanized, non‐mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. European Journal of Immunology. https://doi.org/10.1002/eji.1830230216

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.